FDA digs into semaglutide CV benefits, eye safety ahead of Novo Nordisk drug – s panel review, FiercePharma, eye for pharma.#Eye #for #pharma

Posted On Jan 15 2018 by

FDA digs into semaglutide CV benefits, eye safety ahead of Novo Nordisk drug s panel review It’s not often that a drug company alerts the media to FDA review documents (PDF) filed ahead of an agency advisory panel hearing. But Novo Nordisk did just that Monday as the Danish drugmaker faces questioning about semaglutide, its key follow-up to blockbuster GLP-1 diabetes drug Victoza. A weekly GLP-1 injection, semaglutide is Novo’s answer to the long-acting GLP-1 medications already on the market, particularly Eli Lilly’s Trulicity, which has been siphoning off market share from the long-dominant Victoza. Flagging the FDA documents could …


Siebel Customer Relationship Management (CRM) Applications, Oracle, crm for pharma.#Crm #for #pharma

Posted On Jan 14 2018 by

Siebel Sales Commerce Social Industry Solutions Oracle’s Siebel Customer Relationship Management (CRM), the world’s most complete CRM solution, helps organizations achieve maximum top- and bottom-line growth and deliver great customer experiences across all channels, touchpoints, and devices. Only Oracle can deliver complete, end-to-end customer lifecycle solutions. Siebel CRM delivers transactional, analytical, and engagement features to manage all customer-facing operations. With solutions tailored to more than 20 industries, Siebel CRM delivers comprehensive on-premise and on-demand CRM solutions that are tailored to industry requirements and offer role-based customer intelligence and prebuilt integrations. Siebel CRM plays an important role within the Oracle Customer …


UPM Pharmaceuticals – Formulation Development, CDMO, gmp for pharmaceuticals.#Gmp #for #pharmaceuticals

Posted On Jan 9 2018 by

gmp for pharmaceuticals Proof of Concept Proof of Concept Proof of concept services at UPM are widely recognized for speed, precision and innovative thought across a full spectrum of studies. Based on our client needs, we evaluate a number of parameters for development and manufacture of specific API (active pharmaceutical ingredient) dosage forms based. Brevi-Batch is a cost effective development approach ideal for clients in search of high quality, proof of concept. With a significantly smaller scale than most small-scale R D formulation batches, Brevi-Batch conserves valuable R D API using equipment designed for fast set-up, use, and clean-up. UPM’s …


The GMP Group – One of the top recruitment agencies in Singapore, gmp for pharmaceuticals.#Gmp #for #pharmaceuticals

Posted On Jan 9 2018 by

LATEST JOBS Admin Treasury Settlement Assistant Manager Admin Assistant Senior/ Process Engineer Facility Engineer The GMP Group is one of the largest staffing and HR companies in Singapore. Our “boutique” business units offer their own distinct services to cater to each niche our clients operate in. GMP Recruitment GMP Technologies GMP Banking GMP International GMP Consultancy GSI Executive Search Job seekers Career Tips CV Writing Secrets to Success Career Q A E-Services For employers Request For Staff Knowledge Centre News Updates Testimonials Our engagement with GMP has been very positive As a specialist in air transport communications and IT solutions, …


Axis Pharmaceuticals, gmp for pharmaceuticals.#Gmp #for #pharmaceuticals

Posted On Jan 9 2018 by

gmp for pharmaceuticals DOMESTIC MARKET Axis Pharmaceutical has developed its domestic business through very reliable contacts in the market and has promoted its products very effectively because of its long term association with an expanding network of dealers and distributors throughout Pakistan. Our close association with large and small dealers and distributors has put our products in the forefront of the local pharmaceutical sector. We are proud of our achievements in this sector and are constantly in touch with our marketing people in all major cities of the country who deliver what our valued clients expect. INTERNATIONAL MARKET Having established …


Even for busy doctors, nothing is as good as a rep – for getting pharma info #biopharma #companies

Posted On Jan 8 2018 by

#pharma info # Even for busy doctors, nothing is as good as a rep for getting pharma info If you’re a pharma sales rep, chances are, you’re walking through a fog of existential angst. If you’re not questioning your existence, worrying that you’ll be laid off, or wondering whether the doctors in your territory will stop seeing reps, you know other reps who are. All the surveys and studies–doctors like seeing reps, doctors prefer to read, doctors are unduly influenced, doctors aren’t, e-detailing will or won’t replace reps–probably don’t help, either. But you’ve probably been around long enough to have …


Bilcare Research provides solution for Pharmaceutical Packaging Research #pharmaceutical #market #size

Posted On Jan 8 2018 by

#pharma packaging solutions # Pharma Packaging Innovations The deep customer relationships with the Who’s Who of pharma giants give Bilcare a critical advantage that will benefit us in the long term through cross selling of Bilcare’s patented Pharma Packaging Solutions to global players. We believe Bilcare will become a dominant player in the pharma packaging industry globally in three aspects: market (customer) leadership, geographic reach, and product & solutions offerings. Currently, we are collaborating with global pharmaceutical companies to ensure market competitiveness for their products through brand protection, brand management and brand enhancement strategies in addition to our Optima® services, …


Dublin-based Actavis to buy Forest Labs for $25 billion #recent #pharmaceutical #news

Posted On Jan 7 2018 by

#forest pharma # Dublin-based Actavis to buy Forest Labs for $25 billion Actavis. the world’s second-largest generic-drug maker by market value, is to buy Forest Laboratories in a cash and stock deal valued at about $25 billion. Actavis will pay the equivalent of $89.48 per share, representing a premium of 25 per cent to Forest’s Friday close. The offer comprises $26.04 in cash and 0.3306 Actavis shares for every Forest share. Forest had a market value of $19.3 billion at the close of trading last Friday. Dublin-headquartered Actavis was the most active buyer of drug companies over the past three …


Teva Buys Drug Rival, Barr, for $ Billion #pharmaceuticals #companies

Posted On Jan 7 2018 by

#barr pharma # The New York Times Teva Buys Drug Rival, Barr, for $7.46 Billion July 19, 2008 Teva Pharmaceutical Industries said Friday that it would buy a rival generic drug maker, Barr Pharmaceuticals, for $7.46 billion to expand in both the United States and Europe. The deal is the latest in a wave of consolidation in the generic-drug sector that some analysts suspect will result in only a handful of major global players. Teva, the world’s largest generic drug company, plans to buy Barr for $66.50 a share in cash and stock. The price represents a 42 percent premium …


Sun Pharma inks pact to buy DUSA for $230 million – The Hindu #international #pharma #jobs

Posted On Jan 7 2018 by

#dusa pharma # Sun Pharma inks pact to buy DUSA for $230 million Sun Pharmaceutical Industries, on Thursday, said it had inked a pact to acquire U.S.-based DUSA Pharmaceuticals for around $230 million (about Rs.1,250 crore). Sun Pharma and DUSA Pharmaceuticals have entered into a definitive agreement under which Sun Pharma will acquire DUSA, a dermatology company focused on developing and marketing its Levulan photo-dynamic therapy platform, Sun Pharma said in a statement. Under the terms of the agreement, a 100 per cent subsidiary of Sun Pharma will commence a tender offer for all of the outstanding common stock of …